Form 4: Teva CFO Kalif Reports RSU Vesting and New Equity Grant

Teva Pharmaceutical Industries Ltd.'s Chief Financial Officer, Eliyahu Sharon Kalif, reported the vesting of previously granted restricted share units and the acquisition of new units.

Summary

• Eliyahu Sharon Kalif, EVP and Chief Financial Officer of Teva Pharmaceutical Industries Ltd., reported transactions involving the company's ordinary shares and restricted share units (RSUs).
• On March 4, 2026, 33,512 RSUs, granted on March 4, 2022, vested and were converted into ordinary shares.
• On March 4, 2026, an additional 23,251 RSUs, granted on March 4, 2024, vested and were converted into ordinary shares.
• Following these conversions, Kalif's direct beneficial ownership of ordinary shares increased to 305,519.
• On March 4, 2026, Kalif also acquired 53,175 new Restricted Share Units, which will vest in installments on March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030.
• After all reported transactions, Kalif beneficially owns 46,503 unvested RSUs from the March 4, 2024 grant and 53,175 unvested RSUs from the March 4, 2026 grant.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive, routine compensation event that reinforces executive alignment with long-term company performance and retention, without indicating any immediate operational or financial changes.

Positives

• The vesting of 56,763 Restricted Share Units (33,512 + 23,251) demonstrates the realization of long-term incentive compensation for the Chief Financial Officer.
• The grant of 53,175 new Restricted Share Units aligns the CFO's interests with long-term shareholder value creation and serves as a retention mechanism.
• Increased direct beneficial ownership of ordinary shares to 305,519 indicates continued commitment to the company.

Risks

• Potential for misinterpretation of insider transaction data by the market, despite the routine nature of RSU vesting and grants.
• Risk of non-compliance with Section 16(a) reporting requirements, though this filing indicates compliance.

Future Outlook

The filing details future vesting schedules for newly granted Restricted Share Units, indicating a long-term incentive structure for the Chief Financial Officer extending through March 4, 2030.

Industry Context

StockSavvy.ai notes that the use of Restricted Share Units (RSUs) as a significant component of executive compensation is a common practice in the pharmaceutical industry. This approach aims to align executive incentives with long-term shareholder value and retention, particularly in a sector characterized by long development cycles and regulatory hurdles. Teva's compensation structure for its CFO reflects standard industry practices for attracting and retaining senior talent.

Comparison to Industry Standards

• The RSU grants and vesting schedule for Teva's CFO are consistent with typical long-term incentive plans observed in major pharmaceutical companies such as Pfizer, Johnson & Johnson, and Novartis, where equity-based compensation forms a substantial portion of executive pay.
• The multi-year vesting schedule, extending to 2030 for the latest grant, is a standard mechanism to ensure executive retention and incentivize sustained performance, mirroring practices seen in companies like Merck and Bristol Myers Squibb.
• The total number of shares beneficially owned by the CFO, 305,519 ordinary shares, represents a significant stake, comparable to equity holdings of senior executives in similarly sized global pharmaceutical firms, demonstrating a strong alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The vesting and new grant of RSUs align the CFO's interests with long-term shareholder value.
• Employees: No direct impact on general employees, but reflects the company's executive compensation strategy.

Next Steps

• Future vesting of 23,251 Restricted Share Units on March 4, 2027, and 23,253 on March 4, 2028, from the March 4, 2024 grant.
• Future vesting of 13,293 Restricted Share Units on March 4, 2027, March 4, 2028, March 4, 2029, and 13,296 on March 4, 2030, from the March 4, 2026 grant.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Trading, Restricted Share Units, RSU, Executive Compensation, Eliyahu Sharon Kalif, CFO, Equity Grant, Stock Ownership